1
|
Kodithuwakku KAHT, Owada H, Miura H, Maruyama D, Hirano K, Suzuki Y, Kobayashi Y, Koike S. Effects of oral administration of timothy hay and psyllium on the growth performance and fecal microbiota of preweaning calves. J Dairy Sci 2021; 104:12472-12485. [PMID: 34538491 DOI: 10.3168/jds.2021-20259] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 08/09/2021] [Indexed: 12/12/2022]
Abstract
The objective of this study was to evaluate the effects of oral administration of fiber from the first week of life on the growth and hindgut environment of preweaning calves. Twenty newborn female Holstein calves were divided into 2 groups as control and treatment. Calves in both groups were reared under the same feeding program except for oral fiber administration. Timothy hay and psyllium were mixed at a 50-to-6 ratio as a treatment diet for oral fiber administration. Calves in the treatment group were orally administered 50 g of fiber daily from 3 to 7 d of age and 100 g of fiber from 8 d of age until weaning. Feed intake and occurrence of diarrhea were recorded daily, and body weight (BW) was recorded weekly for the individual calf. Fresh feces were collected from calves at 7, 21, 35, 49, and 56 d of age to analyze fermentation parameters and microbiota to characterize the hindgut environment. Higher fiber intake in the treatment group due to oral administration of timothy and psyllium did not affect the starter intake and achieved higher BW at 21 d of age. The fecal pH, total volatile fatty acid, lactate, and ammonia nitrogen concentrations were not affected by oral fiber administration; meanwhile, the molar proportion of propionate was higher in the treatment group at 7 d of age. The difference in fecal microbiota in the calves subjected to the oral administration of fiber was observed within 21 d of life; Lactobacillus spp. and Prevotella spp. showed higher abundance, whereas that of Clostridium perfringens was decreased. These higher abundances of beneficial bacteria and lower abundance of pathogenic bacteria during early life may partly explain the higher BW of calves in the treatment group at 21 d of age. Furthermore, no adverse effect was observed for the BW and health status in the treatment group throughout the preweaning period. Therefore, early fiber feeding via oral administration potentially contributes to improving the hindgut environment in newborn calves, which leads to better growth of calves during the early stage of life.
Collapse
Affiliation(s)
| | - H Owada
- Central Research Institute for Feed and Livestock, ZEN-NOH, Kasama 319-0205, Japan
| | - H Miura
- Graduate School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan
| | - D Maruyama
- Graduate School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan
| | - K Hirano
- Central Research Institute for Feed and Livestock, ZEN-NOH, Kasama 319-0205, Japan
| | - Y Suzuki
- Graduate School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan
| | - Y Kobayashi
- Graduate School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan
| | - S Koike
- Graduate School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan.
| |
Collapse
|
2
|
Ishitsuka K, Izutsu K, Maruyama D, Makita S, Jacobsen ED, Horwitz S, Kusumoto S, Allen P, Porcu P, Imaizumi Y, Yamauchi N, Morishima S, Kawamata T, Foss FM, Utsunomiya A, Nosaka K, Serbest G, Kato K, Adachi N, Tsukasaki K, Tobinai K. FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS. Hematol Oncol 2021. [DOI: 10.1002/hon.14_2879] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- K Ishitsuka
- Kagoshima University Hospital Department of Hematology and Rheumatology Kagoshima Japan
| | - K Izutsu
- National Cancer Center Hospital Department of Hematology Tokyo Japan
| | - D Maruyama
- National Cancer Center Hospital Department of Hematology Tokyo Japan
| | - S Makita
- National Cancer Center Hospital Department of Hematology Tokyo Japan
| | - E. D Jacobsen
- Dana Farber Cancer Institute Department of Medical Oncology Boston Massachusetts USA
| | - S Horwitz
- Memorial Sloan Kettering Cancer Center Department of Medicine, Lymphoma Service New York New York USA
| | - S Kusumoto
- Nagoya City University Graduate School of Medical Sciences Department of Hematology and Oncology Nagoya Japan
| | - P Allen
- Emory University Winship Cancer Institute Department of Hematology and Medical Oncology Atlanta Georgia USA
| | - P Porcu
- Sidney Kimmel Cancer Center Thomas Jefferson University Department of Medical Oncology Philadelphia Pennsylvania USA
| | - Y Imaizumi
- Nagasaki University Hospital Department of Hematology Nagasaki Japan
| | - N Yamauchi
- National Cancer Center Hospital East Department of Hematology Chiba Japan
| | - S Morishima
- University of the Ryukyus Hospital Department of Hematology and Oncology Okinawa Japan
| | - T. Kawamata
- The Institute of Medical Science The University of Tokyo Department of Hematology Tokyo Japan
| | - F. M Foss
- Yale University School of Medicine, Hematology and Bone Marrow Transplantation New Haven Connecticut USA
| | - A Utsunomiya
- Imamura General Hospital Department of Hematology Kagoshima Japan
| | - K Nosaka
- Kumamoto University Hospital Department of Hematology, Rheumatology, Infectious Disease Kumamoto Japan
| | - G Serbest
- Daiichi Sankyo, Inc, Global Oncology Research & Development Basking Ridge New Jersey USA
| | - K Kato
- Daiichi Sankyo, Inc, Global Oncology Research & Development Basking Ridge New Jersey USA
| | - N Adachi
- Daiichi Sankyo Co, Ltd Oncology Medical Science Department Tokyo Japan
| | - K Tsukasaki
- Saitama Medical University International Medical Center Department of Hematology Saitama Japan
| | - K Tobinai
- National Cancer Center Hospital Department of Hematology Tokyo Japan
| |
Collapse
|
3
|
Nakamura K, Maruyama D. What is the value of health-related quality of life in a negative superiority trial? Ann Oncol 2020; 31:976-977. [PMID: 32485295 DOI: 10.1016/j.annonc.2020.05.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 05/13/2020] [Accepted: 05/15/2020] [Indexed: 11/29/2022] Open
Affiliation(s)
- K Nakamura
- Research Management Division/JCOG Operations Office, Clinical Research Support Office, Tokyo, Japan.
| | - D Maruyama
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
4
|
Shimomura R, Koba Y, Chang W, Koshimizu M, Fujimoto Y, Kawamoto H, Maruyama D, Matsumoto K, Ushiba H, Andoh T, Shinsho K. Thermoluminescence efficiency and glow curves of Cr-doped Al2O3 ceramic TLD for a wide linear energy transfer range. RADIAT MEAS 2020. [DOI: 10.1016/j.radmeas.2020.106356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
5
|
Hatta S, Fukuhara S, Fujino T, Saito Y, Ito Y, Makita S, Munakata W, Maruyama D, Kusumono M, Izutsu K. THE ROLE OF SURVEILLANCE COMPUTED TOMOGRAPHY IN PATIENTS WITH FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.65_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Hatta
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Fukuhara
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - T. Fujino
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - Y. Saito
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - Y. Ito
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Makita
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - W. Munakata
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - D. Maruyama
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - M. Kusumono
- Diagnostic Radiology; National Cancer Center Hospital; Tokyo Japan
| | - K. Izutsu
- Hematology; National Cancer Center Hospital; Tokyo Japan
| |
Collapse
|
6
|
Yamaguchi M, Suzuki R, Oguchi M, Miyazaki K, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Katayama N. CLINICAL OUTCOMES AND DIAGNOSIS-TO-TREATMENT INTERVAL IN PATIENTS WITH NK/T-CELL LYMPHOMA: 7-YEAR FOLLOW-UP OF THE NKEA STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.86_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Yamaguchi
- Department of Hematology and Oncology; Mie University Graduate School of Medicine; Tsu Japan
| | - R. Suzuki
- Oncology and Hematology; Shimane University Hospital; Izumo Japan
| | - M. Oguchi
- Radiation Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan
| | - K. Miyazaki
- Department of Hematology and Oncology; Mie University Graduate School of Medicine; Tsu Japan
| | - S. Taguchi
- Radiation Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan
| | - J. Amaki
- Hematology and Oncology; Tokai University School of Medicine; Kanagawa Japan
| | - T. Maeda
- Hematology; Kurashiki Central Hospital; Kurashiki Japan
| | - N. Kubota
- Hematology; Saitama Cancer Center; Ina Japan
| | - D. Maruyama
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - Y. Terui
- Hematology Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan
| | - N. Sekiguchi
- Comprehensive Cancer Therapy; Shinshu University School of Medicine; Matsumoto Japan
| | - J. Takizawa
- Hematology; Endocrinology and Metabolism, Niigata University Faculty of Medicine; Niigata Japan
| | - H. Tsukamoto
- Hematology; Showa University School of Medicine; Tokyo Japan
| | - T. Murayama
- Hematology; Hyogo Cancer Center; Akashi Japan
| | - T. Ando
- Hematology; Respiratory Medicine and Oncology, Saga University; Saga Japan
| | - H. Matsuoka
- Medical Oncology/Hematology; Kobe University; Kobe Japan
| | - M. Hasegawa
- Radiation Oncology; Nara Medical University; Kashihara Japan
| | - H. Wada
- Hematology; Kawasaki Medical School; Kurashiki Japan
| | - R. Sakai
- Medical Oncology; Kanagawa Cancer Center; Yokohama Japan
| | - Y. Kameoka
- Hematology; Nephrology and Rheumatology, Akita University; Akita Japan
| | - N. Tsukamoto
- Oncology Center; Gunma University Hospital; Maebashi Japan
| | - I. Choi
- Hematology; National Hospital Organization Kyushu Cancer Center; Fukuoka Japan
| | - Y. Masaki
- Hematology and Immunology; Kanazawa Medical University; Kanazawa Japan
| | - K. Shimada
- Hematology and Oncology; Nagoya University School of Medicine; Nagoya Japan
| | - N. Fukuhara
- Hematology & Rheumatology; Tohoku University School of Medicine; Sendai Japan
| | - T. Utsumi
- Hematology; Shiga Medical Center for Adults; Moriyama Japan
| | - N. Uoshima
- Hematology; Japanese Red Cross Kyoto Daini Hospital; Kyoto Japan
| | - Y. Kagami
- Hematology; Toyota Kosei Hospital; Toyota Japan
| | - N. Asano
- Molecular Diagnostics; Shinshu Medical Center; Suzaka Japan
| | - N. Katayama
- Department of Hematology and Oncology; Mie University Graduate School of Medicine; Tsu Japan
| |
Collapse
|
7
|
Marchi E, Tobinai K, Maruyama D, Nagai H, O'Connor O. ANALYSIS OF PUBLISHED TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): AN EVIDENCE BASED DECISION MAKING APPROACH. Hematol Oncol 2019. [DOI: 10.1002/hon.153_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. Marchi
- Center for Lymphoid Malignancies; Columbia University Medical Center; New York United States
| | - K. Tobinai
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - D. Maruyama
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - H. Nagai
- Hematology/Oncology Research; National Hospital Organization Nagoya Medical Center; Nagoya Japan
| | - O.A. O'Connor
- Center for Lymphoid Malignancies; Columbia University Medical Center; New York United States
| |
Collapse
|
8
|
Tachibana H, Uchida Y, Miyakawa R, Yamashita M, Sato A, Kito S, Maruyama D, Noda S, Kojima T, Fukuma H, Shirata R, Okamoto H, Nakamura M, Takada Y, Nagata H, Hayashi N, Takahashi R, Kawai D, Itano M. Multi-institutional comparison of secondary check of treatment planning using computer-based independent dose calculation for non-C-arm linear accelerators. Phys Med 2018; 56:58-65. [PMID: 30527090 DOI: 10.1016/j.ejmp.2018.11.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Revised: 08/31/2018] [Accepted: 11/15/2018] [Indexed: 10/27/2022] Open
Abstract
PURPOSE This report covers the first multi-institutional study of independent monitor unit (MU)/dose calculation verification for the CyberKnife, Vero4DRT, and TomoTherapy radiotherapy delivery systems. METHODS A total of 973 clinical treatment plans were collected from 12 institutions. Commercial software employing the Clarkson algorithm was used for verification after a measurement validation study, and the doses from the treatment planning systems (TPSs) and verification programs were compared on the basis of the mean value ± two standard deviations. The impact of heterogeneous conditions was assessed in two types of sites: non-lung and lung. RESULTS The dose difference for all locations was 0.5 ± 7.2%. There was a statistically significant difference (P < 0.01) in dose difference between non-lung (-0.3 ± 4.4%) and lung sites (3.5 ± 6.7%). Inter-institutional comparisons showed that various systematic differences were associated with the proportion of different treatment sites and heterogeneity correction. CONCLUSIONS This multi-institutional comparison should help to determine the departmental action levels for CyberKnife, Vero4DRT, and TomoTherapy, as patient populations and treatment sites may vary between the modalities. An action level of ±5% could be considered for intensity-modulated radiation therapy (IMRT), non-IMRT, and volumetric modulated arc radiotherapy using these modalities in homogenous and heterogeneous conditions with a large treatment field applied to a large region of homogeneous media. There were larger systematic differences in heterogeneous conditions with a small treatment field because of differences in heterogeneity correction with the different dose calculation algorithms of the primary TPS and verification program.
Collapse
Affiliation(s)
- Hidenobu Tachibana
- Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 277-8577 Chiba, Japan; Radiation Safety and Quality Assurance Division, Hospital East, National Cancer Center, 277-8577 Chiba, Japan.
| | - Yukihiro Uchida
- Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 277-8577 Chiba, Japan.
| | - Ryuta Miyakawa
- Department of Radiology, Saiseikai Yokohamashi Tobu Hospital, 230-8765 Kanagawa, Japan.
| | - Mikiko Yamashita
- Department of Radiological Technology, Kobe City Medical Center General Hospital, 650-0047 Hyogo, Japan.
| | - Aya Sato
- Department of Radiology, Itabashi Chuo Medical Center, 174-0051 Tokyo, Japan
| | - Satoshi Kito
- Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-8677 Tokyo, Japan.
| | - Daiki Maruyama
- Department of Medical Technology, Japanese Red Cross Medical Center, 150-8935 Tokyo, Japan.
| | - Shigetoshi Noda
- Department of Radiology, Kitasato University Hospital, 252-0375 Kanagawa, Japan.
| | - Toru Kojima
- Department of Radiation Oncology, Saitama Cancer Center, 362-0806 Saitama, Japan
| | - Hiroshi Fukuma
- Department of Radiology, Nagoya City University Hospital, 467-8602 Aichi, Japan
| | - Ryosuke Shirata
- Department of Radiation Oncology, Shonan Kamakura General Hospital, 247-8533 Kanagawa, Japan.
| | - Hiroyuki Okamoto
- Department of Radiation Oncology, The National Cancer Center, 104-0045 Tokyo, Japan.
| | - Mitsuhiro Nakamura
- Division of Medical Physics, Department of Information Technology and Medical Engineering, Human Health Sciences, Graduate School of Medicine, Kyoto University, 606-8507 Kyoto, Japan.
| | - Yuma Takada
- Department of Radiology, Ogaki Tokushukai Hospital, 503-0015 Gifu, Japan.
| | - Hironori Nagata
- Department of Radiation Oncology, Shonan Kamakura General Hospital, 247-8533 Kanagawa, Japan
| | - Naoki Hayashi
- School of Health Sciences, Fujita Health University, 470-1192 Aichi, Japan.
| | - Ryo Takahashi
- Department of Radiation Oncology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, 135-8550 Tokyo, Japan.
| | - Daisuke Kawai
- Division of Radiation Oncology, Kanagawa Cancer Center, 241-0815 Kanagawa, Japan
| | - Masanobu Itano
- Department of Radiation Oncology, Funabashi Municipal Medical Center, 273-8588 Chiba, Japan.
| |
Collapse
|
9
|
Toyoda K, Maruyama D, Kurosawa S, Suzuki T, Yuda S, Yamauchi N, Makita S, Fukuhara S, Munakata W, Taniguchi H, Maeshima A, Kobayashi Y, Tobinai K. Fertility and social reintegration after modified CODOX-M/IVAC with or without rituximab: A questionnaire survey of non-Hodgkin lymphoma. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- K. Toyoda
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - D. Maruyama
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Kurosawa
- Department of Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | - T. Suzuki
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Yuda
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - N. Yamauchi
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Makita
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Fukuhara
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - W. Munakata
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - H. Taniguchi
- Department of Pathology; National Cancer Center Hospital; Tokyo Japan
| | - A.M. Maeshima
- Department of Pathology; National Cancer Center Hospital; Tokyo Japan
| | - Y. Kobayashi
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - K. Tobinai
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| |
Collapse
|
10
|
Nozaki K, Maruyama D, Tajima K, Maeshima A, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Tobinai K. LONG-TERM FOLLOW-UP AFTER LOCALIZED RADIOTHERAPY IN PATIENTS WITH TRANSFORMED B-CELL LYMPHOMA TREATED WITH RITUXIMAB-CONTAINING CHEMOTHERAPY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Nozaki
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - D. Maruyama
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - K. Tajima
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - A.M. Maeshima
- Pathology and Clinical Laboratory; National Cancer Center Hospital; Tokyo Japan
| | - J. Itami
- Radiation Oncology; National Cancer Center Hospital; Tokyo Japan
| | - T. Shichijo
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Yuda
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - T. Suzuki
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - K. Toyoda
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - N. Yamauchi
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Makita
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Fukuhara
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - W. Munakata
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - Y. Kobayashi
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - H. Taniguchi
- Pathology and Clinical Laboratory; National Cancer Center Hospital; Tokyo Japan
| | - K. Tobinai
- Hematology; National Cancer Center Hospital; Tokyo Japan
| |
Collapse
|
11
|
Shichijo T, Maruyama D, Tajima K, Yuda S, Maeshima A, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Tobinai K. ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- T. Shichijo
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - D. Maruyama
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - K. Tajima
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Yuda
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - A.M. Maeshima
- Pathology and Clinical Laboratory; National Cancer Center Hospital; Tokyo Japan
| | - T. Suzuki
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - K. Toyoda
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - N. Yamauchi
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Makita
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Fukuhara
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - W. Munakata
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - Y. Kobayashi
- Hematology; National Cancer Center Hospital; Tokyo Japan
| | - H. Taniguchi
- Pathology and Clinical Laboratory; National Cancer Center Hospital; Tokyo Japan
| | - K. Tobinai
- Hematology; National Cancer Center Hospital; Tokyo Japan
| |
Collapse
|
12
|
Shtrahman E, Maruyama D, Olariu E, Fink C, Zochowski M. Understanding spatial and temporal patterning of astrocyte calcium transients via interactions between network transport and extracellular diffusion. Phys Biol 2017; 14:016001. [PMID: 28004641 PMCID: PMC5333993 DOI: 10.1088/1478-3975/aa5565] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Astrocytes form interconnected networks in the brain and communicate via calcium signaling. We investigate how modes of coupling between astrocytes influence the spatio-temporal patterns of calcium signaling within astrocyte networks and specifically how these network interactions promote coordination within this group of cells. To investigate these complex phenomena, we study reduced cultured networks of astrocytes and neurons. We image the spatial temporal patterns of astrocyte calcium activity and quantify how perturbing the coupling between astrocytes influences astrocyte activity patterns. To gain insight into the pattern formation observed in these cultured networks, we compare the experimentally observed calcium activity patterns to the patterns produced by a reduced computational model, where we represent astrocytes as simple units that integrate input through two mechanisms: gap junction coupling (network transport) and chemical release (extracellular diffusion). We examine the activity patterns in the simulated astrocyte network and their dependence upon these two coupling mechanisms. We find that gap junctions and extracellular chemical release interact in astrocyte networks to modulate the spatiotemporal patterns of their calcium dynamics. We show agreement between the computational and experimental findings, which suggests that the complex global patterns can be understood as a result of simple local coupling mechanisms.
Collapse
Affiliation(s)
- E. Shtrahman
- Applied Physics Program, University of Michigan – Ann Arbor 48109, USA
| | - D. Maruyama
- Department of Physics, University of Michigan - Ann Arbor 48109, USA
| | - E. Olariu
- Department of Physics, University of Michigan - Ann Arbor 48109, USA
| | - C.G. Fink
- Department of Physics, Ohio Wesleyan University -- Delaware 43015, USA
- Neuroscience Program, Ohio Wesleyan University -- Delaware 43015, USA
| | - M. Zochowski
- Department of Physics, University of Michigan - Ann Arbor 48109, USA
- Biophysics Program, University of Michigan - Ann Arbor 48109, USA
| |
Collapse
|
13
|
Maruyama D, Yamazaki S, Honda E, Suzuki E, Hommatsu K, Oshiba R, Sato N. [Basic Study on Visibility and Water Equivalency of a New Colorless Transparent Bolus for Electron Radiotherapy]. Nihon Hoshasen Gijutsu Gakkai Zasshi 2017; 73:194-201. [PMID: 28331147 DOI: 10.6009/jjrt.2017_jsrt_73.3.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Boluses used in electron radiotherapy need to have radiation field visibility and water equivalence. In this report, we have examined field visibility and water equivalence of a new colorless transparent bolus. We examined field visibility, water equivalence, and dose profile. Field visibility was evaluated by comparison to conventional bolus. Water equivalence was investigated by a measured fluence scaling factor. The dose profile was measured by using radiochromic film with the bolus and an ionization chamber in water. We confirmed that the irradiation field could clearly be seen through the transparent colorless bolus. The bolus did not cast a field edge as compared with the conventional bolus. The fluence scaling factor was less than 0.8% as compared to water. We confirmed that the colorless transparent bolus was treated as a water equivalent material. The percentage depth dose (PDD) measured by using radiochromic film with the bolus matched the PDD measured with an ionization chamber in water. R50 was less than 1 mm as compared to PDD measured with an ionization chamber. It was confirmed that the colorless transparent bolus can use to set up patient without losing visibility on flat ground planes. The fluence scaling factor and dose profile measured by using the bolus matched the results measured in water. Therefore, the new colorless transparent bolus has feasibility to improve patient setup efficiency and can improve calculation accuracy by using the fluence scaling factor.
Collapse
Affiliation(s)
- Daiki Maruyama
- Department of Medical Technology, Japanese Red Cross Medical Center
| | | | | | | | | | | | | |
Collapse
|
14
|
Honda T, Maruyama D, Kurihara H, Maeshima A, Yuda S, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Saito Y, Tobinai K. 288O Role of FDG-PET/CT and gastrointestinal endoscopy in the staging of diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv526.04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Ueda R, Maruyama D, Maeshima A, Miyamoto K, Fukuhara S, Kim SW, Watanabe T, Kobayashi Y, Taniguchi H, Tobinai K. Testicular and Leptomeningeal Relapse as Myeloid Sarcoma in a Patient Initially Diagnosed with T Lymphoblastic Lymphoma. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Hiramoto N, Kobayashi Y, Nomoto J, Maruyama D, Watanabe T, Tochigi N, Furuta K, Takeda K, Chuman H, Yagyu S, Hosoi H, Tobinai K. Ewing Sarcoma Arising After Treatment of Diffuse Large B-cell Lymphoma. Jpn J Clin Oncol 2013; 43:417-21. [DOI: 10.1093/jjco/hyt011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Maruyama D, Tobinai K. How we Improve Further the Therapeutic Outcomes of Patients with B-Cell Non-Hodgkin Lymphoma in the Rituximab-ERA? Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32162-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
18
|
Terui Y, Ogura M, Tobinai K, Hatake K, Suzuki T, Maruyama D, Miyazato A, Katsura K, Hotta T. Phase I study of ofatumumab (OFA) in Japanese patients (JPN pts) with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Yaguchi H, Hsu DSH, Maruyama D, Sakaida Y, Sassa S, Sakamoto R, Wang W, Huang CY, Wu WB, Shih CL, Ho BC. Development of Carbon Rich Spin-on Sidewall Material. J PHOTOPOLYM SCI TEC 2010. [DOI: 10.2494/photopolymer.23.193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
20
|
Mori M, Kobayashi Y, Maeshima AM, Gotoda T, Oda I, Kagami Y, Bennett S, Nomoto J, Azuma T, Yokoyama H, Maruyama D, Kim SW, Watanabe T, Matsuno Y, Tobinai K. The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma. Ann Oncol 2009; 21:1500-1505. [PMID: 20022910 DOI: 10.1093/annonc/mdp557] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Information on the clinical behavior of the recently proposed primary duodenal follicular lymphoma (DFL) is limited. PATIENTS AND METHODS Demographic data, signs, symptoms, disease stage, and treatment of the patients diagnosed in National Cancer Center Hospital from 1999 to 2007 were collected and analyzed. RESULTS Twenty-seven patients were studied. Nineteen patients were asymptomatic at the time of diagnosis. Twenty patients had stage I disease. The histological grade was 1 or 2 in 26 patients. IgH/BCL2 fusion was shown in 20 of the examined 24 cases (83%). Fourteen patients received therapy upon diagnosis (local radiotherapy in 2 patients and chemotherapy in 12 including rituximab therapy), their response rate was 85%, and the estimated progression-free survival (PFS) rate at 3 years was 70%. One patient developed histological transformation. The other 13 patients were followed up; their estimated PFS rate at 3 years was 74%. Five among six cases responded to treatment even after progressive disease. All 27 patients have survived with a median follow-up time of 47.9 months. CONCLUSIONS The majority of primary DFL patients have a localized tumor of low-grade histology and are positive for t(14;18). Watchful waiting might be an alternative approach for its indolent course; however, further studies are warranted.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 18/genetics
- Cytogenetic Analysis
- Disease Progression
- Duodenal Neoplasms/genetics
- Duodenal Neoplasms/pathology
- Duodenal Neoplasms/therapy
- Female
- Humans
- Incidence
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/pathology
- Lymphoma, Follicular/therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local/genetics
- Neoplasm Recurrence, Local/pathology
- Neoplasm Recurrence, Local/therapy
- Neoplasm Staging
- Radiotherapy Dosage
- Retrospective Studies
- Survival Rate
- Translocation, Genetic/genetics
- Treatment Outcome
Collapse
Affiliation(s)
- M Mori
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Y Kobayashi
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan.
| | - A M Maeshima
- Division of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
| | - T Gotoda
- Division of Endoscopy, National Cancer Center Hospital, Tokyo, Japan
| | - I Oda
- Division of Endoscopy, National Cancer Center Hospital, Tokyo, Japan
| | - Y Kagami
- Division of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - S Bennett
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J Nomoto
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - T Azuma
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - H Yokoyama
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - D Maruyama
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - S-W Kim
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - T Watanabe
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Y Matsuno
- Division of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
| | - K Tobinai
- Division of Hematology, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
21
|
Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R, Usui E, Koido K, Kim S, Tanosaki R, Tobinai K, Teshima T, Takaue Y. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. Transpl Infect Dis 2008; 10:252-9. [DOI: 10.1111/j.1399-3062.2007.00291.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Yokoyama H, Fukuda T, Kobayashi Y, Kim SW, Maruyama D, Mori SI, Watanabe T, Tanosaki R, Tajima K, Tobinai K, Takaue Y. 287: Hematopoietic Cell Transplantation (HCT) for Chemoradiotherapy-Related Myelodysplastic Syndrome and Acute Leukemia: A Single-Center Analysis of 47 Patients. Biol Blood Marrow Transplant 2008. [DOI: 10.1016/j.bbmt.2007.12.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
23
|
Fukuda T, Maruyama D, Kato R, Yamasaki S, Usui E, Kim SW, Mori SI, Tanosaki R, Tajima K, Taniguchi S, Takaue Y. Allogeneic hematopoietic cell transplantation for the treatment of hematologic malignancies not in remission: The anti-tumor effect of reduced-intensity conditioning is comparable to that of conventional myeloablative conditioning. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Kagami Y, Maeshima A, Matsuno Y, Tobinai K. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 2006; 17:135-40. [PMID: 16236754 DOI: 10.1093/annonc/mdj025] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The majority of lymphomas in the ocular adnexa are low-grade B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma). Although radiotherapy is the most frequently applied management, cataract and dry eye are problematic complications. PATIENTS AND METHODS Between 1973 and 2003, the clinical features of 36 patients with ocular adnexal MALT lymphoma with no symptoms who were managed with no initial therapy after biopsy or surgical resection were retrospectively analyzed. RESULTS The median patient age was 63 years (range 22-84) and all patients had stage I disease, consisting of 31 unilateral cases and five bilateral cases. With a median follow-up of 7.1 years, 25 (69%) did not require treatment. The median time until the initiation of treatment in the remaining 11 patients (31%) was 4.8 years. Six patients (17%) died, and among them only two (6%) died due to progressive lymphoma. Seventeen patients (47%) progressed, but histologic transformation was recognized in only one (3%). The estimated overall survival rates of the 36 patients after 5, 10 and 15 years were 94%, 94% and 71%, respectively. CONCLUSIONS In selected patients with ocular adnexal MALT lymphoma, no initial therapy might be an acceptable approach, because 70% of patients remained untreated at a median of 8.6 years, and their survival was comparable to that of reports on immediate therapy.
Collapse
Affiliation(s)
- K Tanimoto
- Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital and Research Institute, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ando T, Kodera N, Takai E, Maruyama D, Saito K, Toda A. A high-speed atomic force microscope for studying biological macromolecules. Proc Natl Acad Sci U S A 2001; 98:12468-72. [PMID: 11592975 PMCID: PMC60077 DOI: 10.1073/pnas.211400898] [Citation(s) in RCA: 561] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The atomic force microscope (AFM) is a powerful tool for imaging individual biological molecules attached to a substrate and placed in aqueous solution. At present, however, it is limited by the speed at which it can successively record highly resolved images. We sought to increase markedly the scan speed of the AFM, so that in the future it can be used to study the dynamic behavior of biomolecules. For this purpose, we have developed a high-speed scanner, free of resonant vibrations up to 60 kHz, small cantilevers with high resonance frequencies (450-650 kHz) and small spring constants (150-280 pN/nm), an objective-lens type of deflection detection device, and several electronic devices of wide bandwidth. Integration of these various devices has produced an AFM that can capture a 100 x 100 pixel(2) image within 80 ms and therefore can generate a movie consisting of many successive images (80-ms intervals) of a sample in aqueous solution. This is demonstrated by imaging myosin V molecules moving on mica (see http://www.s.kanazawa-u.ac.jp/phys/biophys/bmv_movie.htm).
Collapse
Affiliation(s)
- T Ando
- Department of Physics, Faculty of Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
| | | | | | | | | | | |
Collapse
|
26
|
Sakata-Haga H, Kanemoto M, Maruyama D, Hoshi K, Mogi K, Narita M, Okado N, Ikeda Y, Nogami H, Fukui Y, Kojima I, Takeda J, Hisano S. Differential localization and colocalization of two neuron-types of sodium-dependent inorganic phosphate cotransporters in rat forebrain. Brain Res 2001; 902:143-55. [PMID: 11384607 DOI: 10.1016/s0006-8993(01)02290-9] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We studied by immunohistochemistry the distribution of differentiation-associated sodium-dependent inorganic phosphate (Pi) cotransporter (DNPI) in the rat forebrain, in comparison with brain-specific cotransporter (BNPI). DNPI-staining was principally seen in axonal synaptic terminals which showed a widespread but discrete pattern of distribution different from that of the BNPI-staining. In the diencephalon, marked DNPI-staining was seen in the dorsal lateral geniculate, medial geniculate, ventral posterolateral, ventral posteromedial, anterior, and reticular thalamic nuclei without the colocalization with BNPI-staining. DNPI-staining showed a strong mosaical pattern and overlapped well the BNPI-staining in the medial habenular nucleus. DNPI-staining was moderate over the hypothalamus and notably localized in neurosecretory terminals containing corticotropin-releasing hormone in the median eminence. In contrast, the BNPI-staining was region-related and strong in the ventromedial and mammillary nuclei. In the telencephalon, laminar DNPI-staining was seen over the neocortex, corresponding to the thalamocortical termination, and also found in the retrosplenial cortex and the striatum, with the highest intensity in the accumbens nucleus shell. The present results suggest that DNPI serves as a dominant Pi transport system in synaptic terminals of diencephalic neurons including thalamocortical and thalamostriatal pathways as well as the hypothalamic neuroendocrine system in the rat forebrain.
Collapse
Affiliation(s)
- H Sakata-Haga
- Department of Anatomy, School of Medicine, University of Tokushima, 770-8503, Tokushima, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Hisano S, Hoshi K, Ikeda Y, Maruyama D, Kanemoto M, Ichijo H, Kojima I, Takeda J, Nogami H. Regional expression of a gene encoding a neuron-specific Na(+)-dependent inorganic phosphate cotransporter (DNPI) in the rat forebrain. Brain Res Mol Brain Res 2000; 83:34-43. [PMID: 11072093 DOI: 10.1016/s0169-328x(00)00194-7] [Citation(s) in RCA: 291] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
We have analyzed expression of a gene encoding a brain-specific Na(+)-dependent inorganic phosphate cotransporter (DNPI), which was recently cloned from human brain, in rat forebrain using in situ hybridization. The expression of DNPI mRNA showed a widespread but highly heterogeneous pattern of distribution in the forebrain, where hybridization signals were observed in neurons but not in any other types of cells. Neurons expressing the mRNA were far more numerous in the diencephalon than in the telencephalon. In the thalamus, a number of neurons with high levels of signals were localized to all nuclei of the dorsal thalamus, habenular nuclei and subthalamic nucleus, but not the reticular nucleus and zona incerta. Moderate signal levels were seen in many neurons throughout the hypothalamus, particularly the ventromedial, paraventricular, supraoptic and arcuate nuclei, lateral hypothalamic area and mammillary complex. In contrast, expression of DNPI mRNA in the telencephalon was generally at a low level and occurred locally in some restricted regions within the neocortex, retrosplenial cortex, piriform cortex, olfactory regions, hippocampal formation and medial amygdaloid nucleus. The present results suggest that DNPI functions in heterogeneous neuron populations as a neuron-specific Na(+)-dependent inorganic phosphate cotransport system predominantly expressed in the diencephalon of the rat.
Collapse
Affiliation(s)
- S Hisano
- Laboratory of Neuroendocrinology, Institute Basic Medical Sciences, University of Tsukuba, Tennodai 1-1-1, Tsukuba, 305-8575, Ibaraki, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Chen L, Maruyama D, Sugiyama M, Sakai T, Mogi C, Kato M, Kurotani R, Shirasawa N, Takaki A, Renner U, Kato Y, Inoue K. Cytological characterization of a pituitary folliculo-stellate-like cell line, Tpit/F1, with special reference to adenosine triphosphate-mediated neuronal nitric oxide synthase expression and nitric oxide secretion. Endocrinology 2000; 141:3603-10. [PMID: 11014214 DOI: 10.1210/endo.141.10.7710] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
An immortal nonhormone-producing cell line with a characteristic star-shaped morphology, named Tpit/F1, was derived from an anterior pituitary gland of a temperature-sensitive large T antigen transgenic mouse. To characterize Tpit/F1 cells, we performed cytological studies, which revealed that Tpit/F1 cells express the messenger RNAs of neruonal nitric oxide (NO) synthase, S-100 protein, basic fibroblast growth factor, and pituitary-restricted transcription factor. The Tpit/F1 cells response to pituitary adenylate cyclase-activating peptide comprised the stimulated secretion of interleukin-6. Furthermore, glucocorticoids stimulate glutamine synthase production by Tpit/F1 cells. Considering these cytological characteristics together with their morphology, we deduced that Tpit/F1 cells are derived from pituitary folliculo-stellate (FS) cells. Our cytophysiological analyses of Tpit/F1 cells revealed that intracellular Ca2+ increased dose dependently on ATP administration (0-100 microM), and that this effect did not require the presence of extracellular Ca2+ and was not abolished by treatment with gadolinium, a Ca2+ channel blocker. The ATP-induced increase in intracellular Ca2+ ([Ca2+]i) was completely abolished by treatment with the Ca2+-adenosine triphosphatase (Ca2+-ATPase) inhibitor thapsigargin, which suggests that ATP increases [Ca2+]i by mobilizing internally stored Ca2+ followed by an influx of Ca2+. Moreover, UTP was equipotent with ATP in causing the [Ca2+]i increase in Tpit/F1 cells. Also, the Ca2+ response was prevented by the phospholipase C inhibitor, U-73122, but not by its inactive analog, U-73343. From these results we therefore concluded that ATP acts on Tpit/F1 cells via P2Y2-purinoceptors. Interestingly, both neuronal nitric oxide synthase messenger RNA and NO secretion were increased by ATP administration (10 and 100 microM). These results suggest the biological significance of the topological colocalization of FS cells and endocrine cells. Namely, ATP is cosecreted with hormones from endocrine cells and stimulates NO production by FS cells, and the released NO may regulate neighboring endocrine cell and blood vessels.
Collapse
Affiliation(s)
- L Chen
- Department of Regulation Biology, Faculty of Science, Saitama University, Urawa, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Saito H, Furuta S, Nagata A, Yoshizawa S, Nishizawa K, Ichikawa S, Aizawa T, Yoda H, Maruyama D, Koike Y. [Clinical evaluation of imipenem/cilastatin sodium against severe infections complicating hematological disorders and solid tumors]. Jpn J Antibiot 1991; 44:899-911. [PMID: 1920815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Imipenem/cilastatin sodium (IPM/CS) was administered to a total of 67 patients with severe infections complicating hematological disorders and solid tumors. Fifty patients are included in the present analysis of efficacy and 64 in that of safety. 1. Out of 31 patients with hematological disorders, responses were excellent in 10 patients, good in 10 patients, and the efficacy rate was 64.5%. Out of 19 patients with solid tumors, responses were excellent in 8 patients, good in 8 patients and the efficacy rate was 84.2%. 2. For patients whose responses to other antibiotics had been poor, the efficacy rate was 59.3% in the group with hematological disorders and 62.5% in the group with solid tumors. 3. The relationship between the neutrophil count and efficacy was studied in the patients with hematological disorders. The efficacy rate for 8 patients whose neutrophil counts were 500/mm3 or less was 75.0%. 4. For the patients with hematological disorders, the efficacy rate for patients from whom causative organisms were isolated was 70.0% and that for patients for whom they were unknown was 61.9%. 5. Adverse reactions were observed in 3 patients and abnormal laboratory test results in 2 patients. However, they were mild and disappeared after discontinuation of this drug. From these results, IPM/CS is considered to be a useful antibiotic for the treatment of severe infections complicating hematological disorders and solid tumors.
Collapse
Affiliation(s)
- H Saito
- Second Department of Internal Medicine, School of Medicine, Shinsyu University
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Tsukasa S, Noguchi M, Yonezawa Y, Nakamura Y, Maruyama D, Asakura T, Samejima T, Ohi H, Otsuji M, Nishimata H. [The study of x-ray findings in experimental ischemic enteritis--with special reference to deformity of the intestinal canal and its pathogenesis]. Rinsho Hoshasen 1987; 32:485-93. [PMID: 3613182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
31
|
Tsukasa S, Yonezawa Y, Maruyama D, Asakura T, Noguchi M, Nakamura Y, Otsuji M, Nishimata Y, Hashimoto S. [Niche-like protrusion in x-ray images of the colon]. Rinsho Hoshasen 1986; 31:155-7. [PMID: 3702108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|